Restless Legs Syndrome: Detection and Management in Primary Care



FREE PREVIEW Log in or buy this issue to read the full article. AAFP members and paid subscribers get free access to all articles. Subscribe now.


FREE PREVIEW Subscribe or buy this issue. AAFP members and paid subscribers get free access to all articles.

Am Fam Physician. 2000 Jul 1;62(1):108-114.

  Related Editorial

Restless legs syndrome (RLS) is a neurologic movement disorder that is often associated with a sleep complaint. Patients with RLS have an irresistible urge to move their legs, which is usually due to disagreeable sensations that are worse during periods of inactivity and often interfere with sleep. It is estimated that between 2 and 15 percent of the population may experience symptoms of RLS. Primary RLS likely has a genetic origin. Secondary causes of RLS include iron deficiency, neurologic lesions, pregnancy and uremia. RLS also may occur secondarily to the use of certain medications. The diagnosis of RLS is based primarily on the patient's history. A list of questions that may be used as a basis to assess the likelihood of RLS is included in this article. Pharmacologic treatment of RLS includes dopaminergic agents, opioids, benzodiazepines and anticonvulsants. The primary care physician plays a central role in the diagnosis and management of RLS.

Restless legs syndrome (RLS) is a common, underdiagnosed and treatable condition. A neurologic movement disorder, RLS is often associated with a sleep complaint.1 Patients with RLS may suffer an almost irresistible urge to move the legs, usually due to disagreeable leg sensations that are worse during inactivity and often interfere with sleep.2 RLS may be described as an agitated inability to rest that can have a negative impact on quality of life by causing waking discomfort, chronic sleep deprivation and stress. This article provides science-based information about RLS and its assessment and management in the primary care setting.

Consequences of RLS

Direct adverse effects of RLS include discomfort, sleep disturbances and fatigue.3 These consequences have a secondary impact on functioning by affecting occupational activities, social activities and family life. Disrupted sleep and an inability to tolerate sedentary activities can lead to job loss, a compromised ability to enjoy life and problems with relationships.

Prevalence

RLS is a common disorder. Although the exact prevalence is uncertain, limited studies have indicated that 2 to 15 percent of the population may experience RLS symptoms.46 This wide range of results may be due to differences in study methodologies.

Although the prevalence of RLS increases with age,6 it has a variable age of onset and can occur in children.7 In patients with severe RLS, one third to two fifths had their first symptom before 20 years of age,8 although the precise diagnosis of RLS was made much later.

Etiology

PRIMARY RLS

RLS is a central nervous system disorder.9 It is not caused by psychiatric factors or by stress but may contribute to or be exacerbated by these conditions. There is a high incidence of familial cases of RLS, suggesting a genetic origin for primary RLS.8 The exact mode of inheritance is unknown.8,10

SECONDARY CAUSES OF RLS

Iron Deficiency. RLS may be associated with iron deficiency. A patient's iron stores may be deficient without significant anemia. Recent studies have shown that decreased iron stores (indicated by serum ferritin levels below 50 ng per mL [50 μg per L] can exacerbate RLS symptoms.11,12 Patients with newly diagnosed RLS or RLS patients with a recent exacerbation of symptoms should have their serum ferritin levels measured.

Neurologic Lesions. RLS has been reported in association with spinal cord and peripheral nerve lesions, although an exact pathologic mechanism has not been identified. RLS also may occur in patients with vertebral disk disease.8

Pregnancy. RLS affects up to 19 percent of women during pregnancy.13 Symptoms can be severe but usually subside within a few weeks postpartum.

Uremia. RLS occurs in up to 50 percent of patients with end-stage renal failure and may be particularly bothersome during dialysis when the patient is confined to a resting position.14,15 Improvement in symptoms of RLS has been seen after renal transplantation.16

Drug-Induced. Some evidence from published case reports indicates that RLS symptoms may be induced or exacerbated by medications such as tricyclic antidepressants,17 selective serotonin reuptake inhibitors (SSRIs),18 lithium19 and dopamine antagonists.20 Caffeine also has been implicated in the worsening of RLS symptoms.21

Assessment and Diagnosis

The diagnosis of RLS is based primarily on the patient's history. Often, patients do not bring RLS symptoms to the physician's attention; therefore, it can be helpful to include general sleep questions in the review of systems (Table 1). When RLS is suspected, more specific questions should be asked (Table 2).

TABLE 1

Sleep/Wake Profile

How has the patient been sleeping recently? (Ask the patient and bed partner.)

Suggested questions following a sleep complaint

When did the problem begin? (To determine acute vs. chronic insomnia)

Does the patient have a psychiatric or medical condition that may cause insomnia?

Is the sleep environment conducive to sleep? (Relates to noise, interruptions, temperature, light)

Does the patient report “creeping, crawling or uncomfortable, difficult-to-describe feelings” in the legs or arms that are relieved by moving them? (Relates to restless legs syndrome)

Does the bed partner report that the patient's legs or arms jerk during sleep? (Relates to periodic limb movements of sleep)

Does the patient snore loudly, gasp, choke or stop breathing during sleep? (Relates to obstructive sleep apnea)

Is the patient a shift worker? What are the work hours? (Relates to circadian sleep disorders/sleep deprivation)

What times does the patient go to bed and get up on weekdays and weekends? (Relates to poor sleep hygiene and sleep deprivation)

Does the patient use caffeine, tobacco or alcohol? Does the patient take over-the-counter or prescription medications, such as stimulating antidepressants, steroids, decongestants or beta-blockers? (Relates to substance-induced insomnia)

Signs of sleepiness

What daytime consequences, such as fatigue, sleepiness, confusion or difficulty concentrating, does the patient report?

Does the patient report dozing off or have difficulty staying awake during routine tasks, especially while driving?

TABLE 1   Sleep/Wake Profile

View Table

TABLE 1

Sleep/Wake Profile

How has the patient been sleeping recently? (Ask the patient and bed partner.)

Suggested questions following a sleep complaint

When did the problem begin? (To determine acute vs. chronic insomnia)

Does the patient have a psychiatric or medical condition that may cause insomnia?

Is the sleep environment conducive to sleep? (Relates to noise, interruptions, temperature, light)

Does the patient report “creeping, crawling or uncomfortable, difficult-to-describe feelings” in the legs or arms that are relieved by moving them? (Relates to restless legs syndrome)

Does the bed partner report that the patient's legs or arms jerk during sleep? (Relates to periodic limb movements of sleep)

Does the patient snore loudly, gasp, choke or stop breathing during sleep? (Relates to obstructive sleep apnea)

Is the patient a shift worker? What are the work hours? (Relates to circadian sleep disorders/sleep deprivation)

What times does the patient go to bed and get up on weekdays and weekends? (Relates to poor sleep hygiene and sleep deprivation)

Does the patient use caffeine, tobacco or alcohol? Does the patient take over-the-counter or prescription medications, such as stimulating antidepressants, steroids, decongestants or beta-blockers? (Relates to substance-induced insomnia)

Signs of sleepiness

What daytime consequences, such as fatigue, sleepiness, confusion or difficulty concentrating, does the patient report?

Does the patient report dozing off or have difficulty staying awake during routine tasks, especially while driving?

TABLE 2

Questions That May Aid in the Diagnosis of Restless Legs Syndrome (RLS)

Does the patient report “creeping, crawling or uncomfortable, difficult-to-describe feelings” in the legs or arms that are relieved by moving or rubbing them?

Is there a correlation between RLS symptoms and time of day? Do the symptoms worsen with rest or inactivity?

Do sensations interfere with sleep onset or returning to sleep?

What daytime consequences does the patient report (e.g., fatigue, sleepiness, confusion, lack of attention)?

Does the bed partner report that the patient's legs or arms jerk during sleep? (Relates to periodic limb movements of sleep.)

Does the patient have secondary causes of RLS, such as low iron stores, diabetes mellitus, kidney disease or pregnancy?

Are neurologic symptoms or diagnoses present?

Is there a relationship between symptoms and medications, such as tricyclic antidepressants or selective serotonin reuptake inhibitors?

Was the onset of symptoms correlated with a change in medication?

Do family members report similar symptoms? Have any family members been diagnosed with RLS?

TABLE 2   Questions That May Aid in the Diagnosis of Restless Legs Syndrome (RLS)

View Table

TABLE 2

Questions That May Aid in the Diagnosis of Restless Legs Syndrome (RLS)

Does the patient report “creeping, crawling or uncomfortable, difficult-to-describe feelings” in the legs or arms that are relieved by moving or rubbing them?

Is there a correlation between RLS symptoms and time of day? Do the symptoms worsen with rest or inactivity?

Do sensations interfere with sleep onset or returning to sleep?

What daytime consequences does the patient report (e.g., fatigue, sleepiness, confusion, lack of attention)?

Does the bed partner report that the patient's legs or arms jerk during sleep? (Relates to periodic limb movements of sleep.)

Does the patient have secondary causes of RLS, such as low iron stores, diabetes mellitus, kidney disease or pregnancy?

Are neurologic symptoms or diagnoses present?

Is there a relationship between symptoms and medications, such as tricyclic antidepressants or selective serotonin reuptake inhibitors?

Was the onset of symptoms correlated with a change in medication?

Do family members report similar symptoms? Have any family members been diagnosed with RLS?

Symptoms are described by patients in many ways, with descriptions ranging from “mild” to “intolerable” (Table 3).22 Although most patients experience the sensations in their legs, the sensations also may occur in the arms or elsewhere. RLS symptoms are generally worse in the evening and night and less severe in the morning. RLS must be distinguished from sleep-related leg conditions such as nocturnal leg cramps.

TABLE 3

Terms Used to Describe Sensations of Restless Legs Syndrome

Creeping

Crawling

Itching

Burning

Searing

Tugging

Indescribable

Pulling

Drawing

Aching

Like water flowing

Like worms or bugs crawling under the skin

Like an electric current

Restless

Painful

TABLE 3   Terms Used to Describe Sensations of Restless Legs Syndrome

View Table

TABLE 3

Terms Used to Describe Sensations of Restless Legs Syndrome

Creeping

Crawling

Itching

Burning

Searing

Tugging

Indescribable

Pulling

Drawing

Aching

Like water flowing

Like worms or bugs crawling under the skin

Like an electric current

Restless

Painful

CLINICAL CRITERIA

The criteria for the diagnosis of RLS are based on those developed by the International Restless Legs Syndrome Study Group (Table 4).3

The involuntary, repetitive, periodic, jerking movements refer to periodic limb movements (PLM), also known as PLMS (periodic limb movements of sleep)23 or nocturnal myoclonus,24 which may be associated with RLS. PLMS are stereotyped, repetitive flexions of the limbs (legs alone or legs more than arms) usually occurring during sleep. They occur periodically on an average of every 20 seconds. The most common movement is a dorsiflexion of the ankles and flexion of the knees or hips.

TABLE 4

Clinical Criteria and Associated Features of Restless Legs Syndrome (RLS)

Minimal criteria

A compelling urge to move the limbs, usually associated with paresthesias/dysesthesias

Motor restlessness as seen in activities such as floor pacing, tossing and turning in bed and rubbing the legs

Symptoms that are worse or exclusively present at rest (i.e., lying, sitting) with variable and temporary relief by activity

Symptoms that are worse in the evening and at night

Associated features

Sleep disturbance and daytime fatigue

Normal neurologic examination (in patients with primary RLS)

Involuntary, repetitive, periodic, jerking limb movements, either in sleep or while awake and at rest


Information from Waters AS. Toward a better definition of the restless leg syndrome. Mov Disord 1995; 10:634–42.

TABLE 4   Clinical Criteria and Associated Features of Restless Legs Syndrome (RLS)

View Table

TABLE 4

Clinical Criteria and Associated Features of Restless Legs Syndrome (RLS)

Minimal criteria

A compelling urge to move the limbs, usually associated with paresthesias/dysesthesias

Motor restlessness as seen in activities such as floor pacing, tossing and turning in bed and rubbing the legs

Symptoms that are worse or exclusively present at rest (i.e., lying, sitting) with variable and temporary relief by activity

Symptoms that are worse in the evening and at night

Associated features

Sleep disturbance and daytime fatigue

Normal neurologic examination (in patients with primary RLS)

Involuntary, repetitive, periodic, jerking limb movements, either in sleep or while awake and at rest


Information from Waters AS. Toward a better definition of the restless leg syndrome. Mov Disord 1995; 10:634–42.

PHYSICAL EXAMINATION

The physical examination is usually normal in patients with RLS and is performed to identify secondary causes and to rule out other disorders. The following are areas of particular importance:

  • A neurologic examination with emphasis on spinal cord and peripheral nerve function.

  • A vascular examination to rule out vascular disorders.

LABORATORY TESTS

The following laboratory tests can identify possible secondary causes of RLS:

  • Serum ferritin level of <50 ng per mL (<50 μg per L).

  • Serum chemistry to rule out uremia and diabetes.

A sleep study (polysomnography) is not routinely indicated in the work-up of RLS,25 because RLS is diagnosed on the basis of history and clinical findings.

DIFFERENTIAL DIAGNOSIS

Differential diagnoses may include the following:

  • Nocturnal leg cramps are typically painful, palpable, involuntary muscle contractions, often focal, with a sudden onset; they are usually unilateral.26

  • Akathisia is excessive movement, without specific sensory complaints; it often does not correlate with rest or time of day and usually results from medication such as neuroleptics or other dopamine blocking agents.27

  • Peripheral neuropathy can cause leg symptoms that are different from RLS; they are usually not associated with motor restlessness or helped by movement, and do not worsen in the evening or nighttime. Sensory complaints are typically numbness, tingling or pain. Small fiber sensory neuropathies, as seen in diabetes, are often confused with RLS. Patients with neuropathies may have neuropathic and RLS symptoms.

  • Vascular disease, such as deep venous thrombosis.

Treatment

The severity of RLS varies from patient to patient. Although pharmacologic treatment is helpful for many patients with RLS, those with mild symptoms may not need medications. Because no single medication or combination of medications will work predictably for all patients, treatment must be individualized. Physicians and patients may need to work together over time to find the medication or combination of medications and the dosages that will work best. Table 5 lists appropriate pharmacologic agents and their advantages and disadvantages. Therapy for RLS constitutes an “off-label” use of these pharmacologic agents.

TABLE 5

Pharmacologic Treatment for Patients with Restless Legs Syndrome (RLS)

Agent Advantages Disadvantages

Dopaminergic agents

Dopamine precursor combinations such as carbidopa-levodopa

Can be used on a “one-time” basis or as circumstances may require. Useful for persons with intermittent RLS because dopamine agonists take longer to have an effect.

As many as 80 percent of patients who take carbidopa-levodopa may develop augmentation.* Therapeutic effect may be reduced if taken with high-protein food. Can cause insomnia, sleepiness and gastrointestinal problems.

Dopamine agonists such as pergolide, pramipexole, ropinirole

Useful in moderate to severe RLS. Recent reports indicate high efficacy of dopamine agonists, but the role of their long-term use is unknown.29

Can cause severe sleepiness,30 which may limit its use during daytime.

Agonists can cause nausea. To avoid this, slow dosage increase is important, especially for pergolide.

Opioids such as codeine, hydrocodone, oxycodone, propoxyphene, tramadol Benzodiazepines such as clonazepam, temazepam

Can be used on an intermittent basis. Can also be used successfully for daily therapy. Helpful in some patients when other medications are not tolerated and may help improve sleep.

Can cause constipation, urinary retention, sleepiness or cognitive changes. Tolerance and dependence possible with higher doses of stronger agents. Can cause daytime sleepiness and cognitive impairment, particularly in the elderly.

Anticonvulsants such as carbamazepine, gabapentin

Can be considered when dopamine agonists have failed. May be useful in those with coexisting peripheral neuropathy and/or when RLS discomfort is described as pain.

Vary, depending on agent. Gastrointestinal disturbance such as nausea, sedation, dizziness.

Iron (ferrous sulfate)

Use in patients with serum ferritin levels < 50 ng per mL (< 50 μg per L).

Ideal means of administration has not been established. Oral treatment may take several months to be effective and may be poorly tolerated.

Clonidine

May be useful in hypertensive patients.

Has the potential to cause hypotension, dermatitis and sleepiness.


*—Augmentation is a worsening of RLS symptoms in the course of therapy. Symptoms may be more severe and start earlier in the day (e.g., afternoon rather than evening) than before treatment began and may spread to different parts of the body. Augmentation, which can start soon after therapy is begun or not until months or years later, has also been reported with dopamine agonists and may occur with other medications.

TABLE 5   Pharmacologic Treatment for Patients with Restless Legs Syndrome (RLS)

View Table

TABLE 5

Pharmacologic Treatment for Patients with Restless Legs Syndrome (RLS)

Agent Advantages Disadvantages

Dopaminergic agents

Dopamine precursor combinations such as carbidopa-levodopa

Can be used on a “one-time” basis or as circumstances may require. Useful for persons with intermittent RLS because dopamine agonists take longer to have an effect.

As many as 80 percent of patients who take carbidopa-levodopa may develop augmentation.* Therapeutic effect may be reduced if taken with high-protein food. Can cause insomnia, sleepiness and gastrointestinal problems.

Dopamine agonists such as pergolide, pramipexole, ropinirole

Useful in moderate to severe RLS. Recent reports indicate high efficacy of dopamine agonists, but the role of their long-term use is unknown.29

Can cause severe sleepiness,30 which may limit its use during daytime.

Agonists can cause nausea. To avoid this, slow dosage increase is important, especially for pergolide.

Opioids such as codeine, hydrocodone, oxycodone, propoxyphene, tramadol Benzodiazepines such as clonazepam, temazepam

Can be used on an intermittent basis. Can also be used successfully for daily therapy. Helpful in some patients when other medications are not tolerated and may help improve sleep.

Can cause constipation, urinary retention, sleepiness or cognitive changes. Tolerance and dependence possible with higher doses of stronger agents. Can cause daytime sleepiness and cognitive impairment, particularly in the elderly.

Anticonvulsants such as carbamazepine, gabapentin

Can be considered when dopamine agonists have failed. May be useful in those with coexisting peripheral neuropathy and/or when RLS discomfort is described as pain.

Vary, depending on agent. Gastrointestinal disturbance such as nausea, sedation, dizziness.

Iron (ferrous sulfate)

Use in patients with serum ferritin levels < 50 ng per mL (< 50 μg per L).

Ideal means of administration has not been established. Oral treatment may take several months to be effective and may be poorly tolerated.

Clonidine

May be useful in hypertensive patients.

Has the potential to cause hypotension, dermatitis and sleepiness.


*—Augmentation is a worsening of RLS symptoms in the course of therapy. Symptoms may be more severe and start earlier in the day (e.g., afternoon rather than evening) than before treatment began and may spread to different parts of the body. Augmentation, which can start soon after therapy is begun or not until months or years later, has also been reported with dopamine agonists and may occur with other medications.

The selection of pharmacologic agents is influenced by a number of factors, including:

  • Age of the patient. For example, benzodiazepines may cause cognitive impairment in the elderly.

  • Severity of symptoms. Some patients with mild symptoms may elect not to use medications; others may benefit from levodopa or a dopamine agonist. Patients with severe symptoms may require a strong opioid.

  • Frequency or regularity of symptoms.

  • Patients with infrequent symptoms may benefit from a single effective dose of a medication such as an opioid or levodopa, taken as needed.

  • Presence of pregnancy or comorbid illnesses. No controlled clinical trials have assessed the safety and efficacy of medications for RLS or PLMS during pregnancy.28

  • Renal failure. In patients with renal failure, pharmacologic agents are generally safe, but less frequent doses may be needed if drugs are renally excreted. In addition, for dialysis patients, some medications, such as gabapentin, are dialyzable and others, such as propoxyphene, are not.28

Dopaminergic agents are the first-line drugs for most RLS patients. It is important for primary care physicians to educate patients about the nature and actions of the drugs that are prescribed, including side effects and the uncertainty of long-term effects. For example, when dopaminergic agents are prescribed, patients should be informed that although these medications are usually used to treat Parkinson's disease, they also help to relieve RLS symptoms.

RLS medications have received approval from the U.S. Food and Drug Administration for other uses. In many cases, the therapeutic dosages to treat RLS are much lower than those required for the original uses. The starting dose is usually very low and is gradually increased until effective. In addition to the medications listed in Table 5, agents such as vitamin E, folate and magnesium may be useful. Although many nonpharmacologic treatments have been reported by patients to be helpful, there is no scientific evidence that they are useful in the treatment of RLS.

When to Consider Referral

Most cases of RLS can be effectively managed by primary care physicians. If the primary care physician encounters difficulty managing RLS symptoms in a patient, referral to or consultation with a movement disorders specialist or a sleep specialist may be helpful.

Conclusion

The primary care physician plays a central role in the identification and treatment of RLS. Incorporating sleep- and RLS-related questions into the general review of systems can be helpful in diagnosing RLS. An important aspect of treatment is listening to and supporting patients and carefully evaluating their symptoms. Most patients with RLS can obtain symptomatic relief with commonly prescribed medications and support.

The Authors

MICHAEL THORPY, M.D., is the director of the Sleep Disorders Center at Montefiore Medical Center, Bronx, N.Y.

BRUCE L. EHRENBERG, M.D., is the director of the Clinical, EEG, and Sleep Laboratory at Tufts-New England Medical Center, Boston.

WAYNE A. HENING, M.D., Ph.D., is an assistant clinical professor of neurology at UMDNJ–Robert Wood Johnson Medical School, New York.

MARK MAHOWALD, M.D., is the director of the Minnesota Regional Sleep Disorders Center at the Hennepin County Medical Center, Minneapolis.

BETH A. MALOW, M.D., M.S., is an assistant professor in the department of neurology at the University of Michigan Medical School, Ann Arbor.

BARBARA PHILLIPS, M.D., M.S.P.H., is the director of the Sleep Apnea Center at Samaritan Hospital, Lexington, Ky.

CAROLINE RICHARDSON, M.D., is a Robert Wood Johnson Scholars fellow at the University of Michigan Medical School, Ann Arbor.

CAROLINE WELLBERY, M.D., is an assistant professor of family medicine at the Fort Lincoln Family Medical Center, Georgetown University Medical Center, Washington, D.C. MARK HALLETT, M.D., is the clinical director of the National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Md.

JAMES P. KILEY, PH.D., is the director of the National Center on Sleep Disorders Research, National Heart, Lung, and Blood Institute, Bethesda, Md.

CHARLOTTE MCCUTCHEON, M.D., is program director of the Neuroscience Center, National Institute of Neurological Disorders and Stroke, Bethesda, Md.

SUSAN ROGUS, R.N., M.S., is the coordinator of sleep education activities of the Office of Prevention, Education, and Control, National Heart, Lung, and Blood Institute, Bethesda, Md.

Address correspondence to Susan Rogus, R.N., M.S., Sleep Education Activities, NIH, NHLBI/Bldg. 31, Room 4A-16, 31 Center Dr., MSC 2480, Bethesda, MD 20892–2480. Reprints are not available from the authors.

The authors thank Susan Shero, R.N., M.S., for support in the preparation of the manuscript.

[corrected] Logistical support for the Working Group was provided with the assistance of the Restless Legs Syndrome Foundation, Inc., through an unrestricted educational grant from Pharmacia & Upjohn, and Boehringer Ingelheim.

REFERENCES

1. Meissner HH, Riemer A, Santiago SM, Stein M, Goldman MD, Williams AJ. Failure of physician documentation of sleep complaints in hospitalized patients. West J Med. 1998;169:146–9.

2. Ekbom KA. Restless legs syndrome. Neurology. 1960;10:868–73.

3. Walters AS. Toward a better definition of the restless legs syndrome. Mov Disord. 1995;10:634–42.

4. Ekbom KA. Restless legs. A report of 70 new cases. Acta Med Scand. 1950;246(suppl):64–8.

5. Strang RR. The symptom of restless legs. Med J Aust. 1967;1:1211–3.

6. Lavigne GJ, Montplaisir JY. Restless legs syndrome and sleep bruxism: prevalence and association among Canadians. Sleep. 1994;17:739–43.

7. Walters AS, Picchietti DL, Ehrenberg BL, Wagner ML. Restless legs syndrome in childhood and adolescence. Pediatr Neurol. 1994;11:241–5.

8. Walters AS, Hickey K, Maltzman J, Verrico T, Joseph D, Hening W, et al. A questionnaire study of 138 patients with restless legs syndrome: the ‘Night-Walkers’ survey. Neurology. 1996;46:92–5.

9. Chokroverty S, Jankovic J. Restless legs syndrome: a disease in search of identity [Editorial]. Neurology. 1999;52:907–10.

10. Montplaisir J, Boucher S, Poirier G, Lavigne G, Lapierre O, Lesperance P. Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: a study of 133 patients diagnosed with new standard criteria. Mov Disord. 1997;12:61–5.

11. Sun ER, Chen CA, Ho G, Earley CJ, Allen RP. Iron and the restless legs syndrome. Sleep. 1998;21:371–7.

12. Aul EA, Davis BJ, Rodnitzky RL. The importance of formal serum iron studies in the assessment of restless legs syndrome. Neurology. 1998;51:912.

13. Goodman JD, Brodie C, Ayida GA. Restless leg syndrome in pregnancy. BMJ. 1988;297:1101–2.

14. Wetter TC, Stiasny K, Kohnen R, Oertel WH, Trenkwalder C. Polysomnographic sleep measures in patients with uremic and idiopathic restless legs syndrome. Mov Disord. 1998;13:820–4.

15. Winkelman JW, Chertow GM, Lazarus JM. Restless legs syndrome in end-stage renal disease. Am J Kidney Dis. 1996;28:372–8.

16. Yasuda T, Nishimura A, Katsuki Y, Tsuji Y. Restless legs syndrome treated successfully by kidney transplantation—a case report. Clin Transpl. 1986;12:138.

17. Garvey MJ, Tollefson GD. Occurrence of myoclonus in patients treated with cyclic antidepressants. Arch Gen Psychiatry. 1987;44:269–72.

18. Bakshi R. Fluoxetine and restless legs syndrome. J Neurol Sci. 1996;142:151–2.

19. Terao T, Terao M, Yoshimura R, Abe K. Restless legs syndrome induced by lithium. Biol Psychiatry. 1991;30:1167–70.

20. Ward NG. Akathisia associated with droperidol during epidural anesthesia. Anesthesiology. 1989;71:786–7.

21. Lutz EG. Restless legs, anxiety and caffeinism. J Clin Psychiatry. 1978;39:693–8.

22. Ondo W, Jankovic J. Restless legs syndrome: clinicoetiologic correlates. Neurology. 1996;47:1435–41.

23. American Sleep Disorders Association. The international classification of sleep disorders, revised: diagnostic and coding manual. Rochester, Minn.: American Sleep Disorders Association, 1997:65–8.

24. Lugaresi E, Cirignotta F, Coccagna G, Montagna P. Nocturnal myoclonus and restless legs syndrome. Adv Neurol. 1986;43:295–307.

25. Chesson AL, Ferber RA, Fry JM, Grigg-Damberger M, Hartse KM, Hurwitz TD, et al. The indications for polysomnography and related procedures. Sleep. 1997;20:423–87.

26. Riley JD, Antony SJ. Leg cramps: differential diagnosis and management. Am Fam Physician. 1995;52:1794–8.

27. Walters AS, Hening W, Rubinstein M, Chokroverty S. A clinical and polysomnographic comparison of neuroleptic-induced akathisia and the idiopathic restless legs syndrome. Sleep. 1991;14:339–45.

28. Hening W, Allen R, Earley C, Kushida C, Picchietti D, Silber M. The treatment of restless legs syndrome and periodic limb movement disorder. An American Academy of Sleep Medicine Review. Sleep. 1999;22:970–99.

29. Montplaisir J, Nicolas A, Denesle R, Gomez-Mancilla B. Restless legs syndrome improved by pramipexole: a double-blind randomized trial. Neurology. 1999;52:938–43.

30. Frucht S, Rogers JD, Greene PE, Gordon MF, Fahn S. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology. 1999;52:1908–10.



Copyright © 2000 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Article Tools

  • Print page
  • Share this page
  • AFP CME Quiz

Information From Industry

More in Pubmed

Navigate this Article